Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001564590-21-014021
Filing Date
2021-03-18
Accepted
2021-03-18 08:34:37
Documents
89
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K agle-10k_20201231.htm   iXBRL 10-K 3714776
2 EX-4.3 agle-ex43_722.htm EX-4.3 43982
3 EX-4.5 agle-ex45_723.htm EX-4.5 117991
4 EX-21.1 agle-ex211_12.htm EX-21.1 14293
5 EX-23.1 agle-ex231_10.htm EX-23.1 2125
6 EX-31.1 agle-ex311_9.htm EX-31.1 15874
7 EX-32.1 agle-ex321_11.htm EX-32.1 6842
8 GRAPHIC gfrprknp3si5000001.jpg GRAPHIC 82029
9 GRAPHIC gfrprknp3si5000002.jpg GRAPHIC 114290
  Complete submission text file 0001564590-21-014021.txt   12791041

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA agle-20201231.xsd EX-101.SCH 67395
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20201231_cal.xml EX-101.CAL 70790
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20201231_def.xml EX-101.DEF 215316
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20201231_lab.xml EX-101.LAB 540997
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20201231_pre.xml EX-101.PRE 415061
15 EXTRACTED XBRL INSTANCE DOCUMENT agle-10k_20201231_htm.xml XML 2449518
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37722 | Film No.: 21753183
SIC: 2834 Pharmaceutical Preparations